Long-term secondary prophylaxis in children, adolescents and young adults with von Willebrand disease
von Willebrand Disease
Regimen
Concomitant
Prophylactic treatment
DOI:
10.1160/th10-09-0616
Publication Date:
2011-02-08T12:49:41Z
AUTHORS (9)
ABSTRACT
In patients with von Willebrand disease (VWD) replacement therapy factor VIII/von (VWF) concentrates is increasingly applied as prophylactic regimen. Since 2000, 82 consecutively enrolled clinically relevant bleeding episodes (spontaneous, peri- or postoperative) were diagnosed VWD [type 1: 42/82; type 2: 24/82; 3: 13/82; acquired: 3/82]. all patients, decision for initiating prophylaxis was based on a score > 2 prior to diagnosis, concomitant recurrent bleeds associated anaemia in on-demand therapy. We report results secondary VWF 32 [children n=13; adolescents n=7; adults n=12] 4; 15; 13], 15 of which females, and nine these at the reproductive period. Eight treated Humate P® Wilate® (n=24). Median [min-max] dose [vWF:RCo] 40 [20-47] IU/kg, 23 given substitution twice weekly, seven three times week, two children four per week. Within 12-month-period haemoglobin concentrations returned normal values. duration years. Recurrent stopped 31 whereas inhibitors developed one. Following 12-month observation period monthly frequency significantly reduced [3 vs. 0.07; 3 0: p< 0.001], compared pre-prophylaxis/pre-diagnostic The use an effective tolerated treatment modality, highly beneficial VWD, who present events during
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (27)
CITATIONS (28)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....